• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将抑郁症治疗至症状缓解。

Treating depression to remission.

作者信息

Zajecka John M

机构信息

Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA.

出版信息

J Clin Psychiatry. 2003;64 Suppl 15:7-12.

PMID:14658985
Abstract

Over the last several years, the recommended end point in the treatment of depression has become remission. Patients who achieve remission not only enjoy the benefits of decreased disability and improved functioning in work, family, and social situations, they also have a lower risk of disease progression and relapse. Despite the benefits associated with remission, many patients are left with residual symptoms that prevent them from achieving these benefits. Potential obstacles to reaching remission include diagnostic issues, inadequate treatment, lack of adherence to the treatment regimen, satisfaction with partial improvement, and failure to recognize residual symptoms. Strategies for treating to remission include ensuring appropriate diagnosis, setting treatment goals, selecting antidepressants that are more likely to result in remission, providing patient education and adequate treatment, assessing for residual symptoms, and heeding partial response or lack of response by switching or augmenting treatment.

摘要

在过去几年中,抑郁症治疗的推荐终点已变为症状缓解。实现症状缓解的患者不仅能受益于残疾程度降低以及在工作、家庭和社交场合中功能改善,他们疾病进展和复发的风险也更低。尽管症状缓解有诸多益处,但许多患者仍有残留症状,这使他们无法获得这些益处。实现症状缓解的潜在障碍包括诊断问题、治疗不足、未坚持治疗方案、对部分改善感到满意以及未识别残留症状。实现症状缓解的治疗策略包括确保正确诊断、设定治疗目标、选择更有可能实现症状缓解的抗抑郁药、提供患者教育和充分治疗、评估残留症状,以及通过调整或增加治疗来关注部分反应或无反应情况。

相似文献

1
Treating depression to remission.将抑郁症治疗至症状缓解。
J Clin Psychiatry. 2003;64 Suppl 15:7-12.
2
Achieving remission and managing relapse in depression.实现抑郁症的缓解与控制复发
J Clin Psychiatry. 2003;64 Suppl 18:3-7.
3
Treatment of major depression: is improvement enough?重度抑郁症的治疗:改善就足够了吗?
J Clin Psychiatry. 1999;60 Suppl 6:10-4.
4
Enhancing patient outcomes: treatment adherence.改善患者治疗效果:治疗依从性。
J Clin Psychiatry. 1997;58 Suppl 1:11-4.
5
Approaches to the enhancement of patient adherence to antidepressant medication treatment.提高患者对抗抑郁药物治疗依从性的方法。
J Clin Psychiatry. 2000;61 Suppl 2:6-9.
6
The human cost of not achieving full remission in depression.抑郁症未实现完全缓解所带来的人力成本。
Can J Psychiatry. 2004 Mar;49(3 Suppl 1):10S-16S.
7
Depression with physical symptoms: treating to remission.伴有躯体症状的抑郁症:治疗至症状缓解
J Clin Psychiatry. 2003;64 Suppl 7:24-8.
8
Treating partial responders to antidepressant treatment.治疗对抗抑郁药治疗反应不完全者。
J Clin Psychiatry. 2009 Sep;70(9):e31. doi: 10.4088/JCP.8017cc7c.
9
Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression.关于提高抑郁症患者依从性、自我管理能力及治疗效果的共识性建议。
CNS Spectr. 2007 Aug;12(8 Suppl 13):1-27.
10
Objective: remission of depression in primary care The Oreon Study.目的:初级保健中抑郁症的缓解——奥雷翁研究
Eur Neuropsychopharmacol. 2009 Mar;19(3):169-76. doi: 10.1016/j.euroneuro.2008.10.003. Epub 2009 Jan 13.

引用本文的文献

1
Pharmacogenetic testing and counselling in the community pharmacy: mixed-methods study of a new pharmacist-led service.社区药房的药物遗传学检测和咨询:一项新的由药剂师主导的服务的混合方法研究。
Int J Clin Pharm. 2023 Dec;45(6):1378-1386. doi: 10.1007/s11096-023-01596-8. Epub 2023 Jun 20.
2
Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial.药师主导的抗抑郁治疗前预测性遗传药理学检测(PrePGx):一项开放标签、随机对照试验的研究方案。
Trials. 2021 Dec 14;22(1):919. doi: 10.1186/s13063-021-05724-5.
3
Uncovering the Roles of MicroRNAs in Major Depressive Disorder: From Candidate Diagnostic Biomarkers to Treatment Response Indicators.
揭示微小RNA在重度抑郁症中的作用:从候选诊断生物标志物到治疗反应指标
Life (Basel). 2021 Oct 11;11(10):1073. doi: 10.3390/life11101073.
4
Body mass index and atypical balance as predictors of winter depression remission in cognitive-behavioral therapy and light therapy.体质指数和非典型平衡作为认知行为疗法和光照疗法治疗冬季抑郁症缓解的预测指标。
J Affect Disord. 2022 Jan 1;296:9-16. doi: 10.1016/j.jad.2021.08.154. Epub 2021 Sep 25.
5
Untargeted Plasma Metabolomic Profiling in Patients with Major Depressive Disorder Using Ultra-High Performance Liquid Chromatography Coupled with Mass Spectrometry.使用超高效液相色谱-质谱联用技术对重度抑郁症患者进行非靶向血浆代谢组学分析
Metabolites. 2021 Jul 20;11(7):466. doi: 10.3390/metabo11070466.
6
Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated With Antidepressant Efficacy in Major Depressive Disorder.与重度抑郁症抗抑郁疗效相关的有害单核苷酸多态性分析
Front Psychiatry. 2020 Mar 18;11:151. doi: 10.3389/fpsyt.2020.00151. eCollection 2020.
7
The relationship between mental disorders and actual and desired subjective social status.精神障碍与实际和期望的主观社会地位之间的关系。
Epidemiol Psychiatr Sci. 2019 Dec 16;29:e83. doi: 10.1017/S2045796019000805.
8
Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression.咖啡因和选择性腺苷受体拮抗剂作为治疗抑郁症动机症状的新工具
Front Pharmacol. 2018 Jun 1;9:526. doi: 10.3389/fphar.2018.00526. eCollection 2018.
9
Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.氯胺酮作为新一代速效抗抑郁药的一种有前景的原型药物。
Ann N Y Acad Sci. 2015 May;1344(1):66-77. doi: 10.1111/nyas.12718. Epub 2015 Feb 27.
10
Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.维拉佐酮治疗重度抑郁症:对不同症状和严重程度的疗效。
Int Clin Psychopharmacol. 2014 Mar;29(2):86-92. doi: 10.1097/YIC.0000000000000016.